SenzaGen has today published its 2025 Annual Report. A digital copy can be downloaded at www.senzagen.com or read via the link below.

SenzaGen has today published its 2025 Annual Report. A digital copy can be downloaded at www.senzagen.com or read via the link below.

To request a printed copy, please email name and address to IR@senzagen.com.

Contacts

Peter Nählstedt, President and CEO, SenzaGen ABEmail: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00

Tina Dackemark Lawesson, VP Marketing & CommunicationsEmail: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00

About us

SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.

Attachments

SenzaGen 2025 Annual Report